<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642600</url>
  </required_header>
  <id_info>
    <org_study_id>S61338</org_study_id>
    <nct_id>NCT03642600</nct_id>
  </id_info>
  <brief_title>The Gut Microbiome in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testing two different strategies for weight loss intervention and revealing possible changes
      in composition of gut microbiota, in order to provide more insight in the effect of dietary
      changes and weight loss treatments on gut microbiome in overweight and obese women with
      polycystic ovary syndrome (PCOS). The two strategies are:

        -  dietary advice plus myo-inositol and folic acid

        -  dietary advice plus liraglutide, glucagon-like peptide-1 (GLP-1) receptor agonist
           Primary outcome will be weight loss. Secondary outcomes are longitudinal changes in
           clinical features associated with PCOS and metabolic syndrome, longitudinal changes in
           gut microbiome with interventions.

      Subjects will be treated during 16 weeks and follow-up will take 16 weeks after stop of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight loss</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>PCOS</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>dietary advice plus myo-inositol and folic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dietary advice plus liraglutide pen injector</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary advice plus myo-inositol and folic acid</intervention_name>
    <description>dietary advice and lifestyle interventions and myo-inositol</description>
    <arm_group_label>dietary advice plus myo-inositol and folic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dietary advice plus Liraglutide Pen Injector</intervention_name>
    <description>dietary advice and lifestyle interventions and liraglutide pen injector</description>
    <arm_group_label>dietary advice plus liraglutide pen injector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS according to ROtterdam criteria

          -  BMI ≥ 27 kg/m2 and at risk of metabolic syndrome or BMI ≥ 30 kg/m2

        Exclusion Criteria:

          -  pregnancy

          -  pancreatitis (in the past)

          -  oral contraceptive pill use

          -  inflammatory bowel disease

          -  auto-immune disease

          -  immuno-modulatory drugs

          -  antidiabetic drugs

          -  anti-inflammatory drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Lie Fong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Lie Fong, MD, PhD</last_name>
    <phone>+32 16 344975</phone>
    <email>sharon.liefong@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myriam Welkenhuysen, Msc</last_name>
    <phone>+32 16 343544</phone>
    <email>myriam.welkenhuysen@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharon Lie Fong</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sharon Lie Fong, MD</last_name>
      <phone>+3216344975</phone>
      <email>sharon.liefong@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

